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Background: Pocket hematoma is one of the most common complications following cardiac device im-
plantation. This study examined the impact of this complication on in-hospital outcomes following
Implantable Cardioverter Deﬁbrillator (ICD) implantation.
Methods: Data from Nationwide Inpatient Sample (NIS) 2010 was queried to identify all primary im-
plantations of ICDs and Cardiac Resynchronization Therapy Deﬁbrillators (CRT-D) during the year 2010
using ICD-9 codes. We then identiﬁed the patients who experienced a procedure related hematoma
during the hospital stay. We compared the outcomes of the patients with and without a hematoma
complication. All analyses were performed using SPSS 20 complex samples using appropriate weights to
adjust for the complex sampling design of the national database.
Results: Out of a total of 85,276 primary ICD implantations in the year 2010, 2233 (2.6% of the im-
plantations) were complicated by a hematoma. Increased age (p < 0.001), and comorbidities such as
congestive heart failure (odds ratio (OR) e 1.86, p < 0.001), coagulopathy (OR - 2.3, p < 0.001) and renal
failure (OR - 1.52, p < 0.001) were associated with an increased risk of pocket hematoma formation.
Patients who developed a hematoma had a longer hospitalization (9.1 days versus 5.5 days, p < 0.001)
and higher in-hospital costs ($56,545 versus $47,015, p < 0.001) compared to patients who did not have a
hematoma. Overall mortality associated with ICD implantation was low (0.6%), and hematoma formation
did not adversely affect mortality (0.6% versus 0.4%, p ¼ 0.63).
Conclusion: Hematoma occurs infrequently after ICD implantation, however, it adversely impacts the
cost of procedure and length of stay.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
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Implantable Cardioverter deﬁbrillator (ICD) devices are widely
used for preventing sudden cardiac death. The ﬁrst ICD was
implanted in the year 1980 and subsequently randomized clinical
trials have established the role of ICD's in both primary and sec-
ondary prevention of sudden cardiac death [1e4]. The use of the
cardiac devices has signiﬁcantly increased in the recent years; be-
tween 2006 and 2010, around 367,153 ICD devices were implanted
across the country [5].
Implantation of these devices is associated with minor and
major complications. Minor peri-procedural complications include
pocket hematomas, lead dislodgement, conduction block andElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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thorax, pneumothorax, cardiac perforation, device infection,
myocardial infarction, stroke, valve damage, pericardial effusion,
arterio-venous ﬁstula and cardiac arrest [6]. The peri-procedural
adverse events were estimated to be 3.6%, of which pocket hema-
tomas and lead dislodgement were the most commonly observed
adverse events [6]. These complications have been shown to result
in prolongation of hospital stay and increased mortality [6]. The
nationwide incidence of pocket hematomas; predictors of hema-
toma formation and its impact on mortality, length of hospital stay
and utilization not been systematically studied before for ICD
devices.
2. Methods
2.1. Data source
We used the discharge data from the Nationwide Inpatient
Sample (NIS) database for the year 2010 to identify all the patients
who underwent an ICD implantation during their hospital stay. The
NIS database is developed by the Agency for Healthcare Research
and Quality (AHRQ) as part of the Healthcare Cost and Utilization
Project (HCUP) [7,8]. NIS is the largest available inpatient database
in the United States and it contains a 20% stratiﬁed sample of all the
discharges from nonfederal short-term general hospitals, subspe-
cialty hospitals and public hospitals [7]. The sample is stratiﬁed
based on the number of beds, ownership, hospital teaching status,
region, and state [7]. This database accounts for 90% of all the
hospitalizations and the stratiﬁcation method ensures that the
sample is truly representative of the United States population in
general [7]. National estimates can be obtained using appropriate
discharge weight assigned to each record [7]. This database con-
tains demographic information and can include a maximum of 15
diagnostic and procedure codes based on the International Classi-
ﬁcation of Diseases 9th revision, Clinical Modiﬁcation (ICD-9-CM)
and outcomes based on patient discharge records [7]. The data
includes hospital characteristics such as geographic location, bed-
size, teaching status and also outcome variables such as length of
stay, cost of hospitalization, and in hospital mortality for each
hospitalization. Each record is for a single hospitalization and thus
multiple records are possible for an individual with recurrent
hospitalizations.
2.2. Study population
NIS database for the year 2010 was analyzed to identify all the
patients who underwent an ICD implantation during their hospital
stay. Patients who underwent implantation of Implantable Car-
dioverter Deﬁbrillator (ICD) or CRT-D were identiﬁed using the
appropriate ICD-9 codes (ICD- 3794; CRT-0051) in the discharge
records; and were included in the study. We included only denovo
implantation of the devices, and did not include generator changes,
redo, revisions etc. Since there is no universal deﬁning ICD-9 code
for ICD hematoma formation, we did our best to identify the ICD-9
codes which are most consistent with hematoma formation and
used them in the setting of a preselected population of denovo ICD
device implantation. (99,811e99813 - Hemorrhage or hematoma or
seroma complicating a procedure). The study group was then
categorized into patients with and without hematomas. Different
demographic, clinical and hospital characteristics of the individual
discharge records were then delineated and compared between the
patients with and without a pocket hematoma complication.
Clinical comorbidities of the patients receiving ICD implant were
identiﬁed through comorbidity measures derived from the AHRQ
comorbidity software 8(Supplementary File 1 for ICD 9 codes fordifferent clinical co-morbidities). In hospital outcomes including
length of stay, mortality and hospital charges were also compared
between the two groups.
2.3. Data analysis
Statistical analysis was carried out using SPSS complex samples
software (IBM SPSS Statistics for Windows, Version 20.0. Armonk,
NY: IBM Corp). National estimates were projected after applying
appropriate hospital and discharge level weights to NIS sample for
the year 2010. Categorical variables are represented as n (%) and
continuous variables are represented as mean ± SD. The differences
in the two groups with and without pocket hematomas were
compared using chi-square or t-test as and when appropriate.
Regression analysis was then carried out to determine the factors
favoring pocket hematoma formation. Factors that signiﬁcantly
favored hematoma formation on univariate regression were then
included in the multivariate regression. A p value of less than 0.05
was considered statistically signiﬁcant.
3. Results
During the year 2010, a total of 85,276 patients underwent a de-
novo ICD implantation across the nation. These patients formed our
study population. Of these 50,041 were ICD implantations and
35,235 were CRT-D.
3.1. Baseline characteristics
Mean age our study population was 65.8 years and 30% of the
patients were >75 years of age. The study population was pre-
dominantly male (71.9%). When implantation were stratiﬁed by
race, we note that Caucasians constituted for the majority of device
implantation (62%), followed by African Americans (14.3%) and
1other ethnic group (10.6%). Higher number of ICD implantations
were performed in teaching hospitals (60%) compared to non-
teaching hospitals (40%).
3.2. Incidence and predictors of hematoma formation
A total of 2232 (2.7%) ICD implantations were complicated by
pocket hematomas. There was no difference in the rates of hema-
toma formation in ICD versus CRT-D implantations (2.5% versus
2.9%, p ¼ 0.18).
3.2.1. Demographics
Hematomas formed more frequently in higher age groups
(Table 1, p value for trend <0.001 by ordinal regression). There was
no difference in hematoma formation between the two gender
groups (2.5% versus 2.9%, p ¼ 0.2). When stratiﬁed by racial cate-
gories, African Americans (3.0%) had a slightly higher occurrence of
pocket hematomas compared to Caucasians (2.7%) and others
(2.9%), however this difference was not statistically different
(p ¼ 0.83).
3.2.2. Hospital type
Urban hospitals tended to have a higher incidence of hema-
tomas than rural hospitals (2.7% versus 1.9%, p ¼ 0.18), however,
only 5.4% of the ICD implantations were performed in the rural
hospitals. The teaching status didn't affect the hematoma formation
signiﬁcantly; teaching (2.3%) versus non-teaching hospitals (2.8%),
p ¼ 0.11. We stratiﬁed hospitals based on their volume of device
implantations into four quartiles and we didn't ﬁnd any signiﬁcant
difference in the incidence of hematoma across these four quartiles
(p ¼ 0.21).
Table 1
Demographics, hospital and admission type.
No Hematoma Hematoma P value
Demographic variables
Sex
Male 59,748 (97.4%) 1565 (2.6%) 0.19
Female 23,244 (97%) 708 (3.0%)
Age
0e17 498 (99.0%) e 0.001 (p trend)
18e44 5631 (98.5%) 83 (1.5%)
45e64 28,040 (97.6%) 698 (2.4%)
65e4 23,964 (97.5%) 604 (2.5%)
>75 24864 996.0%) 883 (3.4%)
Race
Caucasian 51,452 (97.2%) 1455 (2.8%) 0.04
African American 118,144 (96.9%) 376 (3.1%)
Others 8752 (97.1%) 265 (2.9%)
Hospital Type
Location
Urban 4550 (98%) 93 (2%) 0.2
Rural 77,663 (97.3%) 2152 (2.7%)
Teaching Status
Non-teaching 33,025 (97.6%) 810 (2.4%) 0.17
Teaching 49,186 (97.2%) 1434 (2.8%)
Admission Type
Non Elective 50,503 (97.2%) 1446 (2.8%) 0.2
Elective 32,220 (97.5%) 818 (2.5%)
Device Type
AICD 48,778 (97.5) 1263 (2.5%) 0.18
CRT-D 34,226 (97.1) 1010 (2.9%)
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Univariate analysis showed that congestive heart failure (OR
1.86, p < 0.001), coagulopathy (OR 2.3, p < 0.001), renal failure (OR
1.52, p < 0.001) and peripheral vascular disease (OR 1.4, p ¼ 0.01)
were strongly associated with increased risk of hematoma forma-
tion (Table 2).
3.2.4. Multivariate analysis
Multivariate analysis of all the appropriate demographic and
clinical variables showed that Age (p < 0.001), congestive heart
failure (p ¼ 0.02), coagulopathy (p < 0.001) and renal failure (0.05)
were the independent predictors of hematoma formation following
ICD implantation.
3.3. Impact of hematoma formation on in-hospital outcomes
3.3.1. Length of stay
Overall mean length of stay associated with ICD device im-
plantationwas noted to be 5.56 days. Themean duration of hospital
stay in patients with post procedural hematomas was signiﬁcantly
higher than those without hematomas; 9.1 versus 5.5 days
(p < 0.001) (Fig. 1).
3.3.2. Cost of hospitalization
Overall mean cost of implantation was $47,257. Hospitalization
costs were signiﬁcantly increased in patients who developed he-
matomas; $56,545 compared to $47, 015 in patients without a he-
matoma (p < 0.001) (Fig. 1).
3.3.3. In-hospital mortality
The overall mortality in patients who underwent ICD implan-
tation peri-procedurally was 0.6%. The overall mortality rate was
not signiﬁcantly impacted by hematoma complication (0.6% versus
0.4%, p ¼ 0.63, Fig. 1).
4. Discussion
Main ﬁndings: Our study is the ﬁrst investigation into the na-
tional incidence of post procedure hematoma after ICD implanta-
tion, predictors of this complication and its impact on in-hospital
outcomes. To summarize the important ﬁndings of our study: ICD
implantations are associated with a low rate of hematoma forma-
tion (2.6%). Hematoma formation does not adversely impact mor-
tality, however, it signiﬁcantly increases hospital length of stay (by
3.6 days) and cost of hospitalization (by 21%). Age, heart failure,
pre-existing coagulopathy and renal failure signiﬁcantly increase
the risk of hematoma formation after ICD implantation.
Pocket hematoma is one of the most common peri-procedural
complications associated with cardiac device implantations [6]. A
few studies have reported the incidence of pocket hematomas after
cardiac device implantations to be in the range of 1e5% [6,9,10].
Pocket hematomas in ICD implantations on a nationwide basis was
reported by Peterson et al. in their study based on National Car-
diovascular Data Registry (NCDR) ICD Registry [6]. In their study the
incidence of pocket hematomas were seen in 1% of patients un-
dergoing ICD implantation [6]. The higher rate of hematomas in our
study is likely due to sampling differences between the NCDR and
the NIS databases. The NCDR ICD database collects information on
ICD implantation from hospitals reporting to NCDR, while the NIS
database includes a nationwide stratiﬁed sample from discharge
charts [7,11]. Therefore the NIS database is more likely to provide
the best estimates for the general population.
Elderly patients appear to be at increased risk for hematoma
formation. There was increase in the number of hematomas seen in
patients >75 years and the highest risk was seen in patients >85years [12]. The elderly patients therefore need to be observed
closely for these complications because of the overall higher
adverse events and in hospital mortality associated with ICD im-
plantations in this age group [12]. Elderly individuals have loose
subcutaneous tissues and poor muscle tone and this may likely
contribute to pooling of blood around the device in these in-
dividuals. Hematoma formationwas found to be similar in both the
genders in our study. Peterson et al. in their study did not observe a
difference in hematomas in the two genders [6]. These ﬁndings
were further validated in a prospective study and thus gender does
not affect hematoma formation in patients undergoing cardiac
device implantation [13]. However, elderly females were at an
increased risk of periprocedural complication and in-hospital
mortality [12].
Congestive heart failure was strongly associated with increased
risk for pocket hematomas in our study (OR 2). In an earlier study,
congestive heart failure was not associated with increased risk of
pocket hematomas [14]. Patients with congestive heart failure are
likely to have other comorbidities. Additionally, congestive heart
failure patients with comorbidities such as atrial ﬁbrillation may
require them to be on long-term anticoagulants. The above two
reasons are the likely explanation for our ﬁndings. Renal failure
increases the risk of hematoma and other complications in patients
with cardiac devices [13]. In our study, renal failure increased the
risk of pocket hematomas by 60%. Renal dysfunction has been
shown to increase the risk of bleeding complications in patients
undergoing cardiac procedures and is thought to be mainly due to
platelet dysfunction from uremia [15e17]. Therefore patients with
congestive heart failure and renal failure may need closer moni-
toring after the ICD implantation.
Coagulation abnormalities obviously increase the risk of
bleeding complications such as pocket hematomas. Additionally,
several patients undergoing ICD implantations have other in-
dications for anticoagulation bymeans of antiplatelet agents or oral
anticoagulants. Various studies estimate that nearly 14e35% of the
patients who need cardiac devices are on long-term oral anti-
coagulation [3,18e21]. Device implantation in these patients
Table 2
Clinical characteristics.
Comorbiditya Odds ratio for hematoma formation P value
Rheumatoid arthritis/Collagen vascular diseases 1.4 0.35
Congestive heart failure 2.03 <0.001
Pulmonary disease 0.863 0.221
Coagulopathy 2.3 <0.001
Hypertension 0.957 0.67
Diabetes mellitus 0.86 0.123
Liver disease 1.4 0.359
Renal failure 1.6 <0.001
Peripheral vascular disease 1.4 0.01
Impact of different clinical comorbidities on hematoma formation following pacemaker implantation.
a Variables are AHRQ co-morbidity measures.
Fig. 1. Impact of Hematomas on length of stay, mortality and utilization costs.
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guidelines recommend that patients be bridged to heparin peri-
procedurally to decrease the risk of hematomas [22]. However,
with this approach the risk of hematomas was still high [23e26]. A
few studies have shown that ICD implantation without bridging
with heparin decreased the risk of pocket hematomas [27,28].
BRUISE CONTROL a multicenter randomized clinical trial has
observed that bleeding complications are higher with heparin
bridging strategy compared to continued oral anticoagulation (16%
vs 3.5%, p < 0.001) [21]. Few studies have suggested increase in
hematoma formation with antiplatelet agents [14,29]. Other
studies disagree with this evidence and suggest that this risk does
not increase with antiplatelet agents [30,31]. Dual antiplatelet
agents and periprocedural heparin increase the risk for pocket
hematomas [32]. Our study was limited by the non-availability of
drug history in the NIS database and therefore we could not
differentiate the pocket hematomas based on intake ofanticoagulant drugs.
Pocket hematomas could be benign or lead to further compli-
cations based on the size and other comorbidities. Minor conse-
quences include discomfort and swelling. Major complications
include infection of the hematoma, cardiac device infection and
interventions (evacuation of the hematoma, blood transfusion,
pocket revision or extraction and re-implantation of the device).
Any or all of these will result in increased length of stay as well as
increased costs. In our study, the mean cost of hospitalization
increased by 21% following pocket hematomas. The incremental
cost from hematomas as observed in another study was $7000 33.
The mean length of stays increased by 3.6 days in our study. In an
earlier study the length of stay following hematoma or bleeding
complication increased by 2e3 days [14,33]. The length of stay in
our study is higher compared to other studies, however, the pos-
sibility of additional complications (related and unrelated) cannot
be ruled out.
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be about 0.4e1% [6,33]. The mortality rates estimated in our study
are similar to other studies. Mortality could be due to complications
of pocket hematomas such as infection or additional interventional
procedures needed to relieve the hematoma. It also has to be
remembered that patients undergoing ICD implantation have se-
vere heart failure and infections in these patients are likely to result
in higher mortality.
Limitations
There are several limitations to our study. Firstly, our study
database is an administrative database gathered from discharge
records across the United States. We are therefore limited in terms
of the variables that are contained in this database. Unavailability of
clinical characteristics, medication history, severity of hematomas
and the follow up tests and interventions done in these patients
limits our understanding of the etiology and prognosis of these
hematomas. Secondly, the documentation and coding errors that
could occur during the individuals hospitalization could lead to
erroneous results when using the NIS database [34]. Thirdly, the
patients could have hematoma formation after the discharge from
the hospital and these events are not included in the database for
the individual's discharge and therefore are likely to be missed.
Fourthly, the patients could have hematomas unrelated to the ICD
implantation such as trauma from chest compressions, but could
have been included in the database because these events occurred
during the same hospitalization. Fifthly, the HCUP database does
not include information on procedures which are done on outpa-
tient basis that might have lesser complications. Lastly, the patients
could have other adverse events that may have affected the length
of hospital stay and therefore resulted in higher utilization costs. All
the above factors could affect the results of our study.
5. Conclusions
Pocket hematomas following ICD implantation are infrequent
and are not associated with signiﬁcant increase in mortality.
Elderly, congestive heart failure, renal failure and patients with
coagulopathy are at higher risk of developing these pocket hema-
tomas. Hematoma formation following cardiac device implantation
prolongs the hospital stay signiﬁcantly and is associated with
increased utilization costs.
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